$10.96
21.91%
Nasdaq, Thu, Aug 21 2025
ISIN
US7611234052
Symbol
RSLS

ReShape Lifesciences, Inc. Stock price

$10.96
-0.68 5.84% 1M
-101.04 90.21% 6M
-435.04 97.54% YTD
-964.60 98.88% 1Y
-114,539.04 99.99% 3Y
-742,099.04 100.00% 5Y
-60,910,909.04 100.00% 10Y
-746,171,989.04 100.00% 20Y
Nasdaq, Closing price Thu, Aug 21 2025
+1.97 21.91%

Key metrics

Basic
Market capitalization
$10.6m
Enterprise Value
$8.0m
Net debt
positive
Cash
$2.5m
Shares outstanding
130.0k
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.5 | 0.9
EV/Sales
1.1 | 0.7
EV/FCF
negative
P/B
8.6
Financial Health
Equity Ratio
-5.3%
Return on Equity
2,818.2%
ROCE
-266.8%
ROIC
-623.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$7.2m | $12.2m
EBITDA
$-6.3m | -
EBIT
$-6.3m | $-5.9m
Net Income
$-3.5m | $-50.0k
Free Cash Flow
$-4.5m
Growth (TTM | estimate)
Revenue
-13.9% | 52.7%
EBITDA
47.0% | -
EBIT
47.4% | 11.0%
Net Income
68.3% | 99.3%
Free Cash Flow
68.1%
Margin (TTM | estimate)
Gross
63.7%
EBITDA
-87.5% | -
EBIT
-87.8%
Net
-48.3% | -0.4%
Free Cash Flow
-62.4%
More
EPS
$-44.6
FCF per Share
$-34.4
Short interest
2.2%
Employees
18
Rev per Employee
$450.0k
Show more

Is ReShape Lifesciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,014 stocks worldwide.

ReShape Lifesciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a ReShape Lifesciences, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a ReShape Lifesciences, Inc. forecast:

Hold
50%
Sell
50%

Financial data from ReShape Lifesciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
7.18 7.18
14% 14%
100%
- Direct Costs 2.60 2.60
9% 9%
36%
4.57 4.57
17% 17%
64%
- Selling and Administrative Expenses 9.19 9.19
36% 36%
128%
- Research and Development Expense 1.68 1.68
28% 28%
23%
-6.28 -6.28
47% 47%
-87%
- Depreciation and Amortization 0.02 0.02
82% 82%
0%
EBIT (Operating Income) EBIT -6.30 -6.30
47% 47%
-88%
Net Profit -3.46 -3.46
68% 68%
-48%

In millions USD.

Don't miss a Thing! We will send you all news about ReShape Lifesciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ReShape Lifesciences, Inc. Stock News

Neutral
Business Wire
7 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Therapeutics, Inc. (“Vyome”), a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that it has closed the previously disclosed transaction with ReShape Lifesciences Inc. (Nasdaq: RSLS). The post-merger company will trade at the open of tradi...
Neutral
Business Wire
8 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that The Nasdaq Stock Market has approved its listing upon completion of the Company's previously announced merger with ReShape Lifesciences (Nasdaq: RSLS), which is ex...
Neutral
Business Wire
10 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced its post-closing Board of Directors, expected to take control of the ReShape Lifesciences (NASDAQ: RSLS) public entity on Friday, August 15, 2025, which will be renamed Vyome Hol...
More ReShape Lifesciences, Inc. News

Company Profile

ReShape Lifesciences Inc. operates as a medical device company, which focuses on technology to treat obesity and metabolic diseases. It operates through the following segments: Lap-Band, ReShape Vest and ReShape vBloc. The company was founded on December 2002 and is headquartered in San Clemente, CA.

Head office United States
CEO Paul Hickey
Employees 18
Founded 2002
Website www.reshapelifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today